Abstract:Abstract Introduction: Randomized trials comparing direct oral anticoagulants (DOACs) to low molecular weight heparin demonstrated higher rates of bleeding associated with DOACs, especially in patients with gastrointestinal (GI) malignancies. DOACs differ in location of absorption with apixaban predominately absorbed in the distal small bowel and proximal colon and edoxaban, rivaroxaban and dabigatran absorbed in the proximal GI tract (e.g. stomach and proximal small intestine). No comparative data is available for the DOACs in treatment of cancer-associated thrombosis (CAT). Given the differences in location of absorption, we aimed to assess the association of bleeding in patients with GI malignancy and CAT on apixaban versus those treated with proximally absorbed DOACs (dabigatran, edoxaban, or rivaroxaban). Methods: Using a nationwide cohort of Veterans, we identified patients with active GI malignancy between 2012 and 2018. Using a previously validated algorithm (91% positive predictive value), we identified patients with newly diagnosed VTE. A VTE was considered to occur in the setting of active cancer if the diagnosis occurred (1) within 3 months before cancer diagnosis, (2) within 6 months after cancer diagnosis, or (3) any time after diagnosis of metastatic cancer. We limited the cohort to patients who received at least a 30-day prescription for anticoagulant therapy with apixaban, dabigatran, edoxaban or rivaroxaban. Patients with a prescription for any anticoagulant therapy within 6 months before VTE diagnosis were excluded. We retrospectively followed patients to 30-days after the last DOAC prescription or to death, whichever came first. The primary outcome of interest was clinically significant bleeding while on DOAC therapy. We defined clinically significant bleeding as the presence of an ICD-9 or ICD-10 code for bleeding in any position for an inpatient admission with 3 exceptions: microscopic hematuria, bleeding related to major trauma and metromenorrhgia. We assessed the association between DOAC use and bleeding as a time-to-event outcome while adjusting for the competing risk of non-bleeding related death through the methods of Fine and Gray. Results: Between 2012 and 2018, a total of 215 patients with GI malignancies received a DOAC for treatment of CAT. Eighty-six patients received apixaban and the remaining 129 received a proximally absorbed DOAC with the majority receiving rivaroxaban (80%). Baseline demographics by anticoagulant therapy are listed in Table 1. None of the clinical variables assessed were significantly different between patients on apixaban versus a proximally absorbed DOAC, including variables associated with risk of anticoagulant-related bleeding. Of the 215 patients included, 73% were diagnosed with a distal GI malignancy (colon or lower). During the follow-up period, 43 of 215 patients (20%) experienced a clinically significant bleeding event, 22.1% of patients on apixaban and 18.6% of patients on a proximally absorbed DOAC. Of the 43 bleeding events, 30 were bleeding from the GI tract. In patients on apixaban versus a proximally absorbed DOAC, there was no significant difference in the risk of clinically significant bleeding (hazard ratio (HR) 1.24; 95% confidence interval (CI): 0.67 - 2.21). Similarly, there was no significant difference in the risk of bleeding from the GI tract in patients on apixaban versus a proximally absorbed DOAC (HR 0.90; 95% CI: 0.43 - 1.89). Conclusion: In this study of 215 patients with GI malignancy, we found no significant difference in the risk of bleeding between patients treated with apixaban versus those treated with a proximally absorbed DOAC. The rate of clinically significant bleeding was high (20%) while on DOAC therapy. There is a continued need for future prospective studies evaluating antithrombotic therapy in patients with GI malignancies and CAT. Figure 1 Figure 1. Disclosures Sanfilippo: AstraZeneca: Research Funding; Atellas Pharma Global: Research Funding. Wang: Servier: Membership on an entity's Board of Directors or advisory committees; Leo Pharma: Research Funding.

Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism

Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era

The incidence of major bleeding in adult patients with urogenital and gynecological cancer being treated with direct oral anticoagulants (DOACs): a systematic review

Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer

Edoxaban, Rivaroxaban or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2

Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism

Bleeding Outcomes in Patients with Gastrointestinal Malignancies Treated with Distally Absorbed Versus Proximally Absorbed Direct Oral Anticoagulants

Comparing Anticoagulation Strategies for Venous Thromboembolism Associated With Active Cancer

Management of DOAC-related bleeding in cancer patients: a single center-case series

Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis

Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis

Poster No. 139 Direct Oral Anticoagulant Use in the Treatment of Venous Thromboembolism Associated with Cancer

Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy

The initial high-dose versus maintenance-dose anticoagulation therapy with direct oral anticoagulants for cancer-associated venous thromboembolism: from the COMMAND VTE Registry-2

Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment

Direct Versus Conventional Anticoagulants for Treatment of Cancer Associated Thrombosis: a Pooled and Interaction Analysis Between Observational Studies and Randomized Clinical Trials

Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry

Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study

Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges